I'm entering this bitch session and also exiting i
Post# of 157598

1. CRC design discussions predate Cold to Hot Tumor MOA. If we abandon and change a trial design, we will loose another year, unless done (without abandonment) by DSMB and FDA, with perhaps a nudge or two by Company,. Not up to us at this point.
2. Nobody will be placed into a death sentence by not changing trial design since it includes the current standard of care plus Leronlimab.
3. Perhaps, seeing the full effect of Leronlimab without any ICI will show that we do shit better than you do.
Chazzle Out!

